About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%) Stock is Down 0.96 (0.00%)
Data as of 07/20/17 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $9.75 with a 52 week high of $13.40 and a 52 week low of $7.35.

Recent News

Natera Reports First Quarter 2017 Financial Results - 05/09/17
SAN CARLOS, Calif., May 9, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2017 and ... More»
Natera, Inc. Announces Launch of Vistara Single-Gene Mutation NIPT - 05/08/17
A NIPT to screen for single gene disorders using cfDNA SAN CARLOS, Calif., May 8, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in genetic testing, announced the launch of Vistara, a non-invasive prenatal test (NIPT) to screen single-gene... More»
Natera Announces the Appointment of Gail Marcus as Member of the Board of Directors - 05/04/17
Experienced Healthcare Executive Adds Deep Experience in Managed Care and Market Access SAN CARLOS, Calif., May 4, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced today the appointment of Gai... More»
Natera Inc. Announces First Quarter 2017 Earnings Conference Call - 05/02/17
SAN CARLOS, Calif., May 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its first quarter ended March 31, 2017 after the market close on May 9, 2017. Natera wil... More»
Study in Nature Shows Early Relapse Detection in Lung Cancer Using Natera's Technology for ctDNA Analysis - 04/26/17
Relapse detected up to 347 days earlier than standard of care, with sensitivity and specificity exceeding 90% SAN CARLOS, Calif. and LONDON, April 26, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, a... More»

Upcoming Events

There are currently no events scheduled.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools